FDA rejects Eton’s allergic conjunctivitis drop

The FDA has rejected Eton Pharmaceuticals’ EM-100 for the treatment of ocular itching associated with allergic conjunctivitis, according to a press release.

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing.

The letter did not raise concerns about the clinical data, leaving the company optimistic about EM-100’s future.

“We believe the issues cited in the CRL can be addressed in the coming months, and we remain confident that EM-100 will be available to patients as quickly as possible,” Eton’s CEO Sean Brynjelsen said in the release.

The FDA has rejected Eton Pharmaceuticals’ EM-100 for the treatment of ocular itching associated with allergic conjunctivitis, according to a press release.

Eton’s partner, Bausch Health Companies, which acquired the U.S. rights to EM-100 in February, received a complete response letter from the FDA regarding the filing.

The letter did not raise concerns about the clinical data, leaving the company optimistic about EM-100’s future.

“We believe the issues cited in the CRL can be addressed in the coming months, and we remain confident that EM-100 will be available to patients as quickly as possible,” Eton’s CEO Sean Brynjelsen said in the release.